These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Moussaoui S; Obinu MC; Daniel N; Reibaud M; Blanchard V; Imperato A Exp Neurol; 2000 Dec; 166(2):235-45. PubMed ID: 11085889 [TBL] [Abstract][Full Text] [Related]
4. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. Oida Y; Kitaichi K; Nakayama H; Ito Y; Fujimoto Y; Shimazawa M; Nagai H; Hara H Brain Res; 2006 Apr; 1082(1):196-204. PubMed ID: 16515773 [TBL] [Abstract][Full Text] [Related]
5. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Thomas B; Saravanan KS; Mohanakumar KP Neurochem Int; 2008 May; 52(6):990-1001. PubMed ID: 18164516 [TBL] [Abstract][Full Text] [Related]
7. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Haobam R; Sindhu KM; Chandra G; Mohanakumar KP Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N. Pérez V; Morón J; Pastó M; Unzeta M Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513 [TBL] [Abstract][Full Text] [Related]
9. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity. Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162 [TBL] [Abstract][Full Text] [Related]
11. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378 [TBL] [Abstract][Full Text] [Related]
13. Fucoidan protects against dopaminergic neuron death in vivo and in vitro. Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of ebselen are associated with the regulation of Bcl-2 and Bax proteins in cultured mouse cortical neurons. Xu JH; Hu HT; Liu Y; Qian YH; Liu ZH; Tan QR; Zhang ZJ Neurosci Lett; 2006 May; 399(3):210-4. PubMed ID: 16513270 [TBL] [Abstract][Full Text] [Related]
17. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732 [TBL] [Abstract][Full Text] [Related]
18. Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease. Oyagi A; Oida Y; Hara H; Izuta H; Shimazawa M; Matsunaga N; Adachi T; Hara H Brain Res; 2008 Jun; 1214():169-76. PubMed ID: 18457816 [TBL] [Abstract][Full Text] [Related]
19. Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Kim SJ; Park C; Han AL; Youn MJ; Lee JH; Kim Y; Kim ES; Kim HJ; Kim JK; Lee HK; Chung SY; So H; Park R Hear Res; 2009 May; 251(1-2):70-82. PubMed ID: 19286452 [TBL] [Abstract][Full Text] [Related]
20. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]